<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290810</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00137</org_study_id>
    <secondary_id>NCI-2009-00137</secondary_id>
    <secondary_id>MAYO-MC048C</secondary_id>
    <secondary_id>NCI-7211</secondary_id>
    <secondary_id>CDR0000459933</secondary_id>
    <secondary_id>MC048C</secondary_id>
    <secondary_id>7211</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>N01CM62205</secondary_id>
    <secondary_id>N01CM62207</secondary_id>
    <nct_id>NCT00290810</nct_id>
    <nct_alias>NCT01646996</nct_alias>
    <nct_alias>NCT01664364</nct_alias>
  </id_info>
  <brief_title>Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase II Trial of Bevacizumab to Prevent or Delay Disease Progression in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well bevacizumab works in treating patients with relapsed
      or refractory B-cell chronic lymphocytic leukemia. Monoclonal antibodies, such as
      bevacizumab, can block cancer growth in different ways. Some block the ability of cancer
      cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing
      substances to them. Bevacizumab may also stop the growth of cancer cells by blocking blood
      flow to the cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess the treatment success rate of Bevacizumab in patients with relapsed or refractory
      B-cell chronic lymphocytic leukemia (CLL).

      II. Assess the toxicity associated with this regimen in patients with relapsed or refractory
      CLL

      SECONDARY OBJECTIVES:

      I. Assess sensitivity to apoptosis/cell death of residual B-cell clone during therapy (e.g.
      is treatment selecting out a resistant clone).

      II. Evaluate if the risk stratification parameters (ie immunoglobulin mutational, ZAP-70,
      FISH defects and /or CD38 status) corresponds to both baseline apoptosis/cell death and the
      rates of apoptosis of CLL B-cells when cultured with Bevacizumab.

      III. Examine if Bevacizumab can be synergistic with other chemotherapeutic drugs such as
      chlorambucil or fludarabine.

      IV. Assess if marrow vascularity is increased at entry to study and if it is modulated
      following therapy with Bevacizumab.

      V. Examine the association of VEGF plasma levels at baseline with clinical responses to
      Bevacizumab.

      VI. Examine the levels of VCAM at entry to the study and during treatment with Bevacizumab.

      OUTLINE: This is a multicenter study. Patients receive bevacizumab IV over 30-90 minutes on
      days 1 and 15.

      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
      After completion of study treatment, patients are followed periodically for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR).</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The NCI Working Group criteria will be used to assess response to therapy. A confirmed response is defined as a response documented on 2 consecutive evaluations at least 4 weeks apart.
Complete Response:
No lymphadenopathy
No hepatomegaly or splenomegaly
Absense of constitutional symptoms
Polymorphonuclear leukocytes ≥ 1500/ul
Platelets &gt; 100,000/ul
Hemoglobin &gt; 11.0 gm/dl
Peripheral blood lymphocytes ≤ 4000/uL.
Confirmation by Marrow Aspirate and biopsy.
Complete Clinical Response:
-CR without bone marrow biopsy confirmation.
Nodular Partial Response:
-CR with the presence of residual clonal nodules.
Partial Response requires:
≥ 50% decrease in peripheral blood lymphocyte count
≥ 50% reduction in lymphadenopathy
≥ 50% reduction in size of liver and/or spleen
1 or more of the following:
Polymorphonuclear leukocytes ≥ 1500/ul
Platelets &gt;100,000/ul
Hemoglobin &gt;11.0 gm/dl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity Associated With This Regimen in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).</measure>
    <time_frame>From the date of registration to the to the date of last treatment evaluation, median number of days on treatment was 56 days.</time_frame>
    <description>As per NCI Common Toxicity Criteria for Adverse Effects (CTCAE) Version 3.0, the term toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment. The number of participants experiencing grade 3 or higher toxicity will be reported here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of registration to the date of the event (i.e., death or the date of last follow-up), up to 5 years.</time_frame>
    <description>The Kaplan-Meier method will be used to estimate distributions in the B-CLL population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>From the date of registration to the date of the event (i.e., death or disease progression) or the date of last follow-up, up to 5 years</time_frame>
    <description>Progression is defined as one of the following:
A ≥50% increase in the sum of the products of at least 2 lymph nodes on 2 consecutive determinations 2 weeks apart (at least one node must be ≥2 cm) or the appearance of new palpable lymph nodes, or
A ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin or the appearance of hepatomegaly or splenomegaly which was not previously present, or
The transformation to a more aggressive histology (e.g. Richter's transformation), or
A ≥ 50% increase in the absolute number of circulating lymphocytes.
The Kaplan-Meier method will be used to estimate time to progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>B-cell Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (monoclonal antibody therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (monoclonal antibody therapy)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of B-cell chronic lymphocytic leukemia (CLL)*, as defined by the following
             phenotypic characteristics:

               -  Predominant population of cells share both B-cell antigens (CD19, CD20, or CD23)
                  as well as the T-cell antigen (CD-5), in the absence of other pan-T-cell markers
                  (CD-3, CD-2, etc.)

                    -  Mantle cell lymphoma must be excluded by demonstrating the absence of the
                       t(11;14) by fluorescent in situ hybridization (FISH)

               -  Dim surface immunoglobulin expression

               -  Exclusively kappa and lambda light chains

          -  Peripheral blood absolute lymphocyte count &gt; 5,000/mm^3

               -  Lymphocytosis must consist of small to moderate size lymphocytes, with ≤ 55%
                  prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically

          -  Requires chemotherapy, as indicated by any of the following:

               -  Disease related symptoms, including the following:

                    -  Weight loss ≥ 10% within the previous 6 months

                    -  Extreme fatigue

                    -  Fevers &gt; 100.5°F for 2 weeks without evidence of infection

                    -  Night sweats without evidence of infection

               -  Evidence of progressive marrow failure, as manifested by the development of or
                  worsening anemia (hemoglobin ≤ 10 g/dL) and/or thrombocytopenia (platelet count ≤
                  100,000/mm^3)

               -  Massive (i.e., &gt; 6 cm below left costal margin) or progressive splenomegaly

               -  Measurable and progressive lymphadenopathy

               -  Measurable (i.e., &gt; 5,000/mm^3) and progressive lymphocytosis

          -  Progressive disease or relapsed after or refractory to 1 course of an alkylating
             agent-based or purine nucleoside-based (e.g., fludarabine) regimen

          -  No marrow function attributable to dysplasia related to prior therapy

          -  ECOG performance status 0, 1, or 2

          -  Serum creatinine &lt; 2 mg/dL

               -  If serum creatinine &gt; 1.5 mg/dL but &lt; 2 mg/dL, creatinine clearance must be ≥ 30
                  mL/min

          -  Platelet count &gt; 30,000/mm^3

          -  Direct bilirubin ≤ 2 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other second malignancy within the past 2 years except squamous cell or basal cell
             carcinoma of the skin or in situ carcinoma of the cervix

          -  No New York Heart Association class III or IV heart failure

          -  No blood pressure &gt; 150/90 mm Hg

          -  No unstable angina

          -  No myocardial infarction or stroke within the past 6 months

          -  No clinically significant peripheral vascular disease

          -  No evidence of bleeding diathesis or coagulopathy

          -  No significant traumatic injury within the past 28 days

          -  Urine protein:creatinine (UPC) ratio ≤ 1.0

               -  Patients with a UPC ratio &gt; 1.0 must undergo a 23-hour urine collection and must
                  demonstrate &lt; 1 gram of protein per day

          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
             the past 6 months

          -  No serious, non-healing wound, ulcer, or bone fracture

          -  No active infections requiring oral or intravenous antibiotics

          -  No active bleeding or pathological conditions that carry a high risk of bleeding
             (e.g., known varices)

          -  No thrombocytopenia requiring transfusion

          -  See Disease Characteristics

          -  More than 4 weeks since prior participation in an experimental drug study

          -  At least 8 weeks since prior rituximab

          -  At least 6 weeks since prior chemotherapy

          -  More than 28 days since prior major surgery or open biopsy

          -  More than 7 days since prior minor surgery, fine needle aspirations, or core biopsies

          -  No concurrent major surgery

          -  No concurrent participation in another experimental drug study

          -  Concurrent full-dose warfarin or low molecular weight heparin allowed provided patient
             is on a stable dose AND INR is in range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tait Shanafelt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2006</study_first_submitted>
  <study_first_submitted_qc>February 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <results_first_submitted>March 22, 2013</results_first_submitted>
  <results_first_submitted_qc>March 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2013</results_first_posted>
  <last_update_submitted>April 21, 2014</last_update_submitted>
  <last_update_submitted_qc>April 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirteen patients were accrued to the bevacizumab trial between December 2005 and March 2009.</recruitment_details>
      <pre_assignment_details>One patient never received protocol treatment due to a high protein:creatinine ratio and high 24-hour urine protein excretion. Accordingly, 12 eligible patients were included in the outcome analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Monoclonal Antibody Therapy)</title>
          <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Monoclonal Antibody Therapy)</title>
          <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="60" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR).</title>
        <description>The NCI Working Group criteria will be used to assess response to therapy. A confirmed response is defined as a response documented on 2 consecutive evaluations at least 4 weeks apart.
Complete Response:
No lymphadenopathy
No hepatomegaly or splenomegaly
Absense of constitutional symptoms
Polymorphonuclear leukocytes ≥ 1500/ul
Platelets &gt; 100,000/ul
Hemoglobin &gt; 11.0 gm/dl
Peripheral blood lymphocytes ≤ 4000/uL.
Confirmation by Marrow Aspirate and biopsy.
Complete Clinical Response:
-CR without bone marrow biopsy confirmation.
Nodular Partial Response:
-CR with the presence of residual clonal nodules.
Partial Response requires:
≥ 50% decrease in peripheral blood lymphocyte count
≥ 50% reduction in lymphadenopathy
≥ 50% reduction in size of liver and/or spleen
1 or more of the following:
Polymorphonuclear leukocytes ≥ 1500/ul
Platelets &gt;100,000/ul
Hemoglobin &gt;11.0 gm/dl</description>
        <time_frame>Up to 5 years</time_frame>
        <population>All 12 patients are used in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Monoclonal Antibody Therapy)</title>
            <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR).</title>
          <description>The NCI Working Group criteria will be used to assess response to therapy. A confirmed response is defined as a response documented on 2 consecutive evaluations at least 4 weeks apart.
Complete Response:
No lymphadenopathy
No hepatomegaly or splenomegaly
Absense of constitutional symptoms
Polymorphonuclear leukocytes ≥ 1500/ul
Platelets &gt; 100,000/ul
Hemoglobin &gt; 11.0 gm/dl
Peripheral blood lymphocytes ≤ 4000/uL.
Confirmation by Marrow Aspirate and biopsy.
Complete Clinical Response:
-CR without bone marrow biopsy confirmation.
Nodular Partial Response:
-CR with the presence of residual clonal nodules.
Partial Response requires:
≥ 50% decrease in peripheral blood lymphocyte count
≥ 50% reduction in lymphadenopathy
≥ 50% reduction in size of liver and/or spleen
1 or more of the following:
Polymorphonuclear leukocytes ≥ 1500/ul
Platelets &gt;100,000/ul
Hemoglobin &gt;11.0 gm/dl</description>
          <population>All 12 patients are used in this analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Clinical Response (CCR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nodular Partial Response (nPR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Associated With This Regimen in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).</title>
        <description>As per NCI Common Toxicity Criteria for Adverse Effects (CTCAE) Version 3.0, the term toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment. The number of participants experiencing grade 3 or higher toxicity will be reported here.</description>
        <time_frame>From the date of registration to the to the date of last treatment evaluation, median number of days on treatment was 56 days.</time_frame>
        <population>All 12 participants treated will be used to analyze this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Monoclonal Antibody Therapy)</title>
            <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Associated With This Regimen in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).</title>
          <description>As per NCI Common Toxicity Criteria for Adverse Effects (CTCAE) Version 3.0, the term toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment. The number of participants experiencing grade 3 or higher toxicity will be reported here.</description>
          <population>All 12 participants treated will be used to analyze this endpoint.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The Kaplan-Meier method will be used to estimate distributions in the B-CLL population.</description>
        <time_frame>From the date of registration to the date of the event (i.e., death or the date of last follow-up), up to 5 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Monoclonal Antibody Therapy)</title>
            <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The Kaplan-Meier method will be used to estimate distributions in the B-CLL population.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.75" lower_limit="5.65">Too few events occurred to obtain an estimate.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Progression is defined as one of the following:
A ≥50% increase in the sum of the products of at least 2 lymph nodes on 2 consecutive determinations 2 weeks apart (at least one node must be ≥2 cm) or the appearance of new palpable lymph nodes, or
A ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin or the appearance of hepatomegaly or splenomegaly which was not previously present, or
The transformation to a more aggressive histology (e.g. Richter’s transformation), or
A ≥ 50% increase in the absolute number of circulating lymphocytes.
The Kaplan-Meier method will be used to estimate time to progression.</description>
        <time_frame>From the date of registration to the date of the event (i.e., death or disease progression) or the date of last follow-up, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Monoclonal Antibody Therapy)</title>
            <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Progression is defined as one of the following:
A ≥50% increase in the sum of the products of at least 2 lymph nodes on 2 consecutive determinations 2 weeks apart (at least one node must be ≥2 cm) or the appearance of new palpable lymph nodes, or
A ≥50% increase in the size of the liver and/or spleen as determined by measurement below the respective costal margin or the appearance of hepatomegaly or splenomegaly which was not previously present, or
The transformation to a more aggressive histology (e.g. Richter’s transformation), or
A ≥ 50% increase in the absolute number of circulating lymphocytes.
The Kaplan-Meier method will be used to estimate time to progression.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.8" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Monoclonal Antibody Therapy)</title>
          <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>External ear inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Serum calcium decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pharyngeal examination abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tait Shanafelt, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <email>shanafelt.tait@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

